From the Royal Victoria Eye and Ear Hospital and St Vincent's University Hospital, Dublin, Ireland.
J Cataract Refract Surg. 2014 Jan;40(1):138-42. doi: 10.1016/j.jcrs.2013.11.002.
To determine the use of intracameral cefuroxime at the end of cataract surgery since the beneficial results were first reported by the European Society of Cataract and Refractive Surgeons Endophthalmitis Study Group in 2006, 250 ophthalmic surgeons affiliated with both public and private hospitals and clinics across Europe were surveyed. The questions regarded their awareness of the results of the ESCRS endophthalmitis study and their current use or non-use of intracameral antibiotics in their cataract procedures. Seventy-four percent of respondents said they always or usually use intracameral antibiotics in their cataract surgery procedures. The most frequently cited reasons for not using cefuroxime or other intracameral antibiotics was the lack of an approved commercial preparation and related anxieties regarding the risk of dilution errors and contamination. More than 90% of respondents said they would use cefuroxime if an approved single-unit dose product were commercially available.
为了确定白内障手术结束时是否使用眼内注射头孢呋辛,自 2006 年欧洲白内障和屈光外科医师学会眼内炎研究组首次报告其有益结果以来,对欧洲公立和私立医院和诊所的 250 名眼科外科医生进行了调查。问题涉及他们对 ESCRS 眼内炎研究结果的了解以及他们在白内障手术中是否使用或不使用眼内抗生素。74%的受访者表示,他们在白内障手术中始终或通常使用眼内抗生素。不使用头孢呋辛或其他眼内抗生素的最常见原因是缺乏批准的商业制剂,以及对稀释错误和污染风险的担忧。超过 90%的受访者表示,如果有批准的单剂量产品上市,他们将使用头孢呋辛。